HAYWARD, CA, USA I February 28, 2025 I Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the ...

BOSTON, MA, USA I February 28, 2025 I Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and ...

SHANGHAI, China I7, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for ...

HONG KONG, China I7, 2025 I Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the ...

DONGGUAN, China I February 28, 2025 I Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce ...

First participant with Von Willebrand Disease dosed with HMB-002, a novel subcutaneous therapy designed to increase endogenous von Willebrand Factor and ...

ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target ...

HEFEI, China I February 25, 2025 I Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center ...

Fully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss and ...

INCHEON, Korea I February 24, 2025 I Samsung Bioepis Co., Ltd. today announced that PYZCHIVA ® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States.

RESEARCH TRIANGLE PARK, NC, USA I5, 2025 I Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today ...

SAN JOSE, CA, USA I5, 2025 I BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally “hard-to-drug” targets, announced today a strategic collaboration and ...